Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BESIVANCE safely and effectively. See full prescribing information for BESIVANCE. BESIVANCE ®(besifloxacin ophthalmic suspension), for topical ophthalmic use Initial U.S. Approval: 2009
Medication labelWhy this: Advisory · dailymed-prescription
BESIVANCE ®(besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitisgroup Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections.
- generic_name
- besifloxacin
- product_names
- Besifloxacin
- ndc
- 85766-257, 24208-446, 85766-257-05
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en